Dateline City:
KENILWORTH, N.J.
Presentations Include Results from Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the planned presentations of data from the companys
broad chronic hepatitis C virus (HCV) clinical development programs at
the upcoming International
Liver Congress 2016.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more